Table 2 Multivariate survival analysis in patients treated with total chemotherapy cycle ≤7

Factors of OS

Pvalue

HR

95% CI

Pathological stage (ypIII-II vs. ypI-0)

0.020*

4.237

1.252–14.29

COD (<  460 vs. ≥ 460 mg/m²)

0.021*

1.972

1.106–3.521

CA19–9 (≥ 35 vs. <  35 U/ml)

0.247

1.448

0.774–2.709

TRG (5–3 vs. 2–1)

0.316

1.842

0.558–6.077

Factors of MFS

Pvalue

HR

95% CI

Pathological stage (ypIII-II vs. ypI-0)

0.048*

2.747

1.068–7.812

COD (<  460 vs. ≥ 460 mg/m²)

0.028*

1.763

1.062–2.933

CA19–9 (≥ 35 vs. <  35 U/ml)

0.161

1.503

0.850–2.656

Anemia (yes vs. no)

0.114

1.514

0.906–2.530

TRG (5–3 vs. 2–1)

0.427

1.530

0.536–4.369

Factors of DFS

Pvalue

HR

95% CI

Pathological stage (ypIII-II vs. ypI-0)

0.039*

2.801

1.053–7.462

COD (<  460 vs. ≥ 460 mg/m²)

0.041*

1.637

1.110–2.688

CA19–9 (≥ 35 vs. <  35 U/ml)

0.264

1.381

0.783–2.438

TRG (5–3 vs. 2–1)

0.499

1.398

0.529–3.690